{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:10:37Z","timestamp":1789996237487,"version":"4.0.1"},"reference-count":24,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Androgenetic alopecia (AGA) is one of the most common causes of hair loss in the male population, characterized by progressive baldness. This study was designed to evaluate the tolerability and local skin pharmacokinetics of bimatoprost in two different formulations in male subjects with AGA. Bimatoprost 1% Formulations A and B were applied topically once daily to the scalp and lateral trunk in the same subjects for 14\u2009days. One skin biopsy from each application site was obtained on Day 14 after the final drug application. Eleven participants were dosed in this study, and their skin samples were analyzed for bimatoprost and its acid metabolite. Both formulations achieved at least a 10\u2010fold higher bimatoprost concentration in subcutaneous fat, where the hair papilla is typically situated, than the in\u00a0vitro concentration needed for maximal increased hair growth (42\u2009ng\/g) in isolated hair follicles. Both formulations showed a significant decrease in bimatoprost concentration with increasing distance from the skin surface as expected for a topically applied formulation with no significant differences between Formulations A and B. Bimatoprost acid concentrations in most samples were below the lower limit of quantitation (0.8\u2009ng\/g) for both formulations. All adverse events reported were mild except for increased serum transaminases in one participant, which was moderate and not considered treatment related. In conclusion, there were no significant differences in bimatoprost concentration between Formulations A and B in the epidermis\/dermis layer of the scalp samples from the same study participants, with levels above efficacious concentrations. Treatment with bimatoprost 1% Formulations A and B was well tolerated.<\/jats:p>","DOI":"10.1111\/cts.70710","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T13:51:20Z","timestamp":1787406680000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Local Pharmacokinetics and Tolerability of Topically\u2010Applied Bimatoprost to the Scalp of Male Patients With Androgenetic Alopecia"],"prefix":"10.1111","volume":"19","author":[{"given":"Sana","family":"Khajeh pour","sequence":"first","affiliation":[{"name":"Department of Local Delivery Translational Sciences AbbVie  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Chen","sequence":"additional","affiliation":[{"name":"Former AbbVie employee  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayssa","family":"Attar","sequence":"additional","affiliation":[{"name":"Former AbbVie employee  Irvine California USA"},{"name":"Bausch &amp; Lomb  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Local Delivery Translational Sciences AbbVie  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Borbridge","sequence":"additional","affiliation":[{"name":"Department of Local Delivery Translational Sciences AbbVie  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Local Delivery Translational Sciences AbbVie  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2015.1009892"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-020-02994-4"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijt.ijt_46_17"},{"key":"e_1_2_9_5_1","unstructured":"\u201cLUMIGAN [Package Insert] \u201d Allergan Inc. (2014)."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2010.01522.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(02)00307-7"},{"issue":"7","key":"e_1_2_9_8_1","first-page":"17","article-title":"Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double\u2010Masked Clinical Trials","volume":"8","author":"Wirta D.","year":"2015","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"e_1_2_9_9_1","unstructured":"\u201cSafety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence \u201d National Library of Medicine (US) https:\/\/clinicaltrials.gov\/study\/NCT01064882."},{"key":"e_1_2_9_10_1","unstructured":"\u201cLATISSE [Package Insert] \u201d Allergan Inc. (2014)."},{"key":"e_1_2_9_11_1","unstructured":"\u201cDose Escalation Study of the Safety Tolerability and Pharmacokinetics of Bimatoprost Topical Solution in the Treatment of Androgenetic Alopecia in Men \u201d National Library of Medicine (US) https:\/\/clinicaltrials.gov\/study\/NCT02676310."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001030-00002"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.03030.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-020-01621-5"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cosmetics11020055"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2003.12.014"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09685.x"},{"key":"e_1_2_9_18_1","unstructured":"\u201cSafety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia \u201d National Library of Medicine (US) https:\/\/clinicaltrials.gov\/study\/NCT01189279."},{"key":"e_1_2_9_19_1","unstructured":"\u201cA Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) \u201d National Library of Medicine (US) https:\/\/clinicaltrials.gov\/study\/NCT01904721."},{"key":"e_1_2_9_20_1","unstructured":"\u201cSafety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia \u201d National Library of Medicine (US) https:\/\/clinicaltrials.gov\/study\/NCT01325337."},{"key":"e_1_2_9_21_1","unstructured":"\u201cSafety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss \u201d National Library of Medicine (US) https:\/\/clinicaltrials.gov\/study\/NCT01325350."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.12-218156"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.01.035"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1061178"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-023-03645-3"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70710","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70710","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:44:57Z","timestamp":1789994697000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/cts.70710"],"URL":"https:\/\/doi.org\/10.1111\/cts.70710","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"2026-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70710"}}